Trial · NCT03117517
Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome
NCT03117517, Early phase 1, Completed, Khyber Medical University Peshawar; results first posted 2020-03-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome. Trials, record NCT03117517. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03117517
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome
- NCT number
- NCT03117517
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 106 participants, actual
- Lead sponsor
- Khyber Medical University Peshawar
- Conditions
- Polycystic Ovarian Syndrome
- Interventions
- Metformin, Metformin, Pioglitazone
- First posted
- 2017-04-18
- Last updated
- 2020-03-02
- Results first posted
- 2020-03-02
- Limitations and caveats
- No blinding No measure of visceral adiposity.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cytokines and Chemokines Measurements | Baseline and after 3 Months | IL-6 and IL-8 levels by ELISA method using commercially available kits. |
| Secondary | Hormonal Profiles | Baseine and after 3 Months | Serum level of LH was measure at baseline and after 3 months of treatment |
| Secondary | Insulin Resistance | Baseline and after 3 months | Insulin resistance was measure by calculating HOMA-IR from the data of insulin and sugar levels. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cytokines and Chemokines Measurements | Baseline and after 3 Months | Measurement of IL-6 levels in serum samples at baseline and after 3 months of treatment | pg/ml | GEOMETRIC_MEAN |
| SECONDARY | Hormonal Profiles | Baseine and after 3 Months | Serum LH level at basline | mIU/ml | GEOMETRIC_MEAN |
| SECONDARY | Insulin Resistance | Baseline and after 3 months | Insulin resistance was determined by HOMA-IR | unitless | MEAN |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cytokines and Chemokines Measurements | Metformin | IL-6 levels at baseline | 14.60 | 95% Confidence Interval 12.05 to 17.69 | pg/ml |
| Cytokines and Chemokines Measurements | Metformin, Pioglitazone | IL-6 levels at baseline | 14.12 | 95% Confidence Interval 11.58 to 17.23 | pg/ml |
| Cytokines and Chemokines Measurements | Metformin | IL-6 levels after 3 months of treatment | 12.65 | 95% Confidence Interval 10.61 to 15.08 | pg/ml |
| Cytokines and Chemokines Measurements | Metformin, Pioglitazone | IL-6 levels after 3 months of treatment | 11.12 | 95% Confidence Interval 10.02 to 12.33 | pg/ml |
| Cytokines and Chemokines Measurements | Metformin | IL-8 Llevels at baseline | 61.92 | 95% Confidence Interval 52.95 to 72.41 | pg/ml |
| Cytokines and Chemokines Measurements | Metformin, Pioglitazone | IL-8 Llevels at baseline | 41.86 | 95% Confidence Interval 38.24 to 45.83 | pg/ml |
| Cytokines and Chemokines Measurements | Metformin | IL-8 Llevels after treatment | 32.70 | 95% Confidence Interval 22.99 to 46.50 | pg/ml |
| Cytokines and Chemokines Measurements | Metformin, Pioglitazone | IL-8 Llevels after treatment | 22.00 | 95% Confidence Interval 16.76 to 28.88 | pg/ml |
| Hormonal Profiles | Metformin | LH level at baseline | 5.79 | 95% Confidence Interval 4.95 to 6.77 | mIU/ml |
| Hormonal Profiles | Metformin, Pioglitazone | LH level at baseline | 6.625 | 95% Confidence Interval 5.52 to 7.94 | mIU/ml |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Metformin | 53 | |
| Overall Study | STARTED | Metformin, Pioglitazone | 53 | |
| Overall Study | COMPLETED | Metformin | 48 | |
| Overall Study | COMPLETED | Metformin, Pioglitazone | 49 | |
| Overall Study | NOT COMPLETED | Metformin | 5 | |
| Overall Study | NOT COMPLETED | Metformin, Pioglitazone | 4 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Metformin | 0 | 0 |
| Total, all-cause mortality | Metformin, Pioglitazone | 0 | 0 |
| Total, other adverse events | Metformin | 0 | 0 |
| Total, other adverse events | Metformin, Pioglitazone | 0 | 0 |
| Total, serious adverse events | Metformin | 0 | 0 |
| Total, serious adverse events | Metformin, Pioglitazone | 0 | 0 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03117517
GET https://conductscience.org/api/trials/v1/NCT03117517/registered